Healio

FDA approves Padagis’ generic budesonide rectal foam for ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . Padagis received FDA approval of its abbreviated new drug application for budesonide 2mg rectal foam for the ...
Monthly Prescribing Reference

FDA Accepts NDA for Budesonide Rectal Foam

FDA Accepts NDA for Budesonide Rectal Foam The FDA has accepted Salix's New Drug Application (NDA) for filing for Budesonide 2mg Rectal Foam for the induction of remission in patients with active mild ...
Business Wire

FDA Approves UCERIS® (Budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis

RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration (FDA) has granted final approval for UCERIS® (budesonide) rectal foam ...
Monthly Prescribing Reference

Uceris Rectal Foam for Distal Ulcerative Colitis Granted Tentative Approval

FDA Accepts NDA for Budesonide Rectal Foam Salix announced that the Food and Drug Administration (FDA) has granted tentative approval for Uceris (budesonide) rectal foam for the induction of remission ...
Mena FN

PADAGIS ANNOUNCES FDA APPROVAL AND LAUNCH OF A-RATED GENERIC VERSION OF UCERIS® (BUDESONIDE 2MG RECTAL FOAM)

(MENAFN- PR Newswire) ALLEGAN, Mich., April 28, 2023 /PRNewswire/ -- Padagis today announced the launch of Budesonide 2mg Rectal Foam (generic to Uceris®) with 180-days of Competitive Generic Therapy ...
Yahoo Finance

Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults

LAVAL, QC / ACCESSWIRE / May 23, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced additional Canadian public drug plan listings for Pr ...
The Globe and Mail

New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

LAVAL, QE / ACCESSWIRE / September 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce that following its approval by Health Canada the new treatment Pr UCERIS ® ...